Lexaria Bioscience Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.88
- Today's High:
- $0.9159
- Open Price:
- $0.88
- 52W Low:
- $0.649
- 52W High:
- $3.595
- Prev. Close:
- $0.876
- Volume:
- 14054
Company Statistics
- Market Cap.:
- $7.93 million
- Book Value:
- 0.543
- Revenue TTM:
- $340791
- Operating Margin TTM:
- -2047.2%
- Gross Profit TTM:
- $183556
- Profit Margin:
- 0%
- Return on Assets TTM:
- -60.66%
- Return on Equity TTM:
- -107.72%
Company Profile
Lexaria Bioscience Corp had its IPO on 2006-10-10 under the ticker symbol LEXX.
The company operates in the Healthcare sector and Biotechnology industry. Lexaria Bioscience Corp has a staff strength of 7 employees.
Stock update
Shares of Lexaria Bioscience Corp opened at $0.88 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.88 - $0.92, and closed at $0.92.
This is a +4.54% increase from the previous day's closing price.
A total volume of 14,054 shares were traded at the close of the day’s session.
In the last one week, shares of Lexaria Bioscience Corp have slipped by -8.42%.
Lexaria Bioscience Corp's Key Ratios
Lexaria Bioscience Corp has a market cap of $7.93 million, indicating a price to book ratio of 2.1936 and a price to sales ratio of 65.0074.
In the last 12-months Lexaria Bioscience Corp’s revenue was $340791 with a gross profit of $183556 and an EBITDA of $-6877470. The EBITDA ratio measures Lexaria Bioscience Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lexaria Bioscience Corp’s operating margin was -2047.2% while its return on assets stood at -60.66% with a return of equity of -107.72%.
In Q1.6666666666667, Lexaria Bioscience Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 6.6%.
Lexaria Bioscience Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.08 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lexaria Bioscience Corp’s profitability.
Lexaria Bioscience Corp stock is trading at a EV to sales ratio of 44.3461 and a EV to EBITDA ratio of -1.5638. Its price to sales ratio in the trailing 12-months stood at 65.0074.
Lexaria Bioscience Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $5.24 million
- Total Liabilities
- $1.06 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $33647
- Dividend Payout Ratio
- 0%
Lexaria Bioscience Corp ended 2024 with $5.24 million in total assets and $0 in total liabilities. Its intangible assets were valued at $5.24 million while shareholder equity stood at $4.40 million.
Lexaria Bioscience Corp ended 2024 with $0 in deferred long-term liabilities, $1.06 million in other current liabilities, 8091.00 in common stock, $-44524108.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.16 million and cash and short-term investments were $3.43 million. The company’s total short-term debt was $32,317 while long-term debt stood at $0.
Lexaria Bioscience Corp’s total current assets stands at $4.24 million while long-term investments were $0 and short-term investments were $269560.00. Its net receivables were $172284.00 compared to accounts payable of $1.01 million and inventory worth $0.00.
In 2024, Lexaria Bioscience Corp's operating cash flow was $0 while its capital expenditure stood at $33647.
Comparatively, Lexaria Bioscience Corp paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.92
- 52-Week High
- $3.595
- 52-Week Low
- $0.649
- Analyst Target Price
- $7
Lexaria Bioscience Corp stock is currently trading at $0.92 per share. It touched a 52-week high of $3.595 and a 52-week low of $3.595. Analysts tracking the stock have a 12-month average target price of $7.
Its 50-day moving average was $0.91 and 200-day moving average was $1.86 The short ratio stood at 2.95 indicating a short percent outstanding of 0%.
Around 1360.9% of the company’s stock are held by insiders while 842.4% are held by institutions.
Frequently Asked Questions About Lexaria Bioscience Corp
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and various cannabinoids. The company’s DehydraTECH technology evaluates for a variety of therapeutic indications, including hypertension, heart disease, dementia, and diabetes. It is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is based in Kelowna, Canada.